The HLX01 (rituximab injection) of Shanghai Henlius approved for marketing at the beginning of 2019, becoming the first biosimilar drug in China.

FCN-159 tablet, a new drug of a subsidiary of Fosun Pharma, was approved by the State Food and Drug Administration for clinical trials of advanced solid tumors.

Fosun Pharma cooperated with Marubeni to develop the third-party healthcare market.

Fosun Pharma invested US$106 million in Butterfly Network, Inc., for development of smartphone ultrasound imager.

SPAQ-CO® Disp, a malaria prevention drug for children of Fosun Pharma, was pre-certified by the World Health Organization.